Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey

被引:0
作者
Chao-Feng Chang
Yu-Chen Tseng
Hsin-Hung Huang
Yu-Lueng Shih
Tsai-Yuan Hsieh
Hsuan-Hwai Lin
机构
[1] Tri-Service General Hospital,Division of Gastroenterology, Department of Internal Medicine
[2] National Defense Medical Center,undefined
来源
Internal and Emergency Medicine | 2018年 / 13卷
关键词
Fatty liver; Pancreatic cancer; Abdominal fat; Computed tomography;
D O I
暂无
中图分类号
学科分类号
摘要
Pancreatic cancer is difficult to diagnose in an early stage, and has the highest mortality of all types of cancer. Obesity, high body mass index, and increased abdominal girth are established risk factors. Some studies have postulated that there is a correlation between organ steatosis and pancreatic cancer. This study aims to explore whether nonalcoholic fatty liver disease (NAFLD) is a risk factor and a prognostic factor for pancreatic cancer. The study enrolled 557 patients (143 with and 414 without pancreatic cancer) who were diagnosed between January 2009 and December 2013. We reviewed the abdominal computed tomographic scans of the patients to confirm the diagnosis of NAFLD. Clinical parameters, laboratory data, and personal information were analyzed. NAFLD is an independent risk factor for pancreatic cancer according to adjusted multivariate logistic regression analysis (OR 2.63, 95% CI 1.24–5.58, p = 0.011). The Kaplan–Meier survival curve reveals that patients without NAFLD have longer survival than patients with NAFLD (p = 0.005, log-rank test). NAFLD is positively correlated with pancreatic cancer, a result suggesting that NAFLD may increase the incidence and risk of pancreatic cancer. Patients with pancreatic cancer and NAFLD have poorer overall survival than patients without NAFLD, perhaps, because dysregulated cytokine status leads to progression of pancreatic cancer. NAFLD may be a prognostic factor for pancreatic cancer.
引用
收藏
页码:191 / 197
页数:6
相关论文
共 189 条
  • [1] Siegel RL(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30
  • [2] Miller KD(2004)Epidemiology and prevention of pancreatic cancer Jpn J Clin Oncol 34 238-244
  • [3] Jemal A(2006)The epidemiology of pancreatic cancer in the United States: changes below the surface Aliment Pharmacol Ther 24 87-94
  • [4] Lowenfels AB(2012)Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms Mol Carcinog 51 53-63
  • [5] Maisonneuve P(2006)The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169 1505-1522
  • [6] Shaib Y(2007)Nonalcoholic fatty liver disease as a feature of the metabolic syndrome Roczniki Państwowego Zakładu 58 129-964
  • [7] Davila J(2012)The interaction of hepatic lipid and glucose metabolism in liver diseases J Hepatol 56 952-642
  • [8] El-Serag H(2006)Non-alcoholic steatohepatitis and metabolic syndrome Curr Opin Clin Nutr Metab Care 9 637-97
  • [9] Bracci PM(2007)Hepato-pancreato-biliary fat: the good, the bad and the ugly HPB 9 92-177
  • [10] Cowey S(2012)Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals J Endocrinol Investig 35 748-994